---
ID: P103
Title: Real-World Evidence & Digital Twin Generator
Registry: CLAI-OS Precision Engine (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P103: Real-World Evidence & Digital Twin Generator

## Abstract

Traditional clinical trials are constrained by time, cost, geographic exclusion, and the ethical limitations of placebo assignment; in oncology and severe hematologic disease, progression during control assignment can permanently reduce survival probability. P103 generates synthetic control arms and individualized digital twins using multimodal real-world evidence, with the design goal of reducing placebo exposure while maintaining regulatory-grade scientific validity.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

**Design objectives**

- Synthetic external control arm generation from SEER, Flatiron Health, AACR Project GENIE, TCGA, H3Africa, NHS datasets, national sickle cell registries, claims databases, and local EHR systems, using propensity score matching, Mahalanobis distance, inverse probability treatment weighting, doubly robust estimation, entropy balancing, and Bayesian hierarchical adjustment.
- Digital twin generation using survival neural networks, temporal transformers, Bayesian dynamic systems, graph neural networks, and ensemble probabilistic forecasting to produce expected progression-free survival, toxicity probability, organ failure risk, quality-adjusted survival, and molecular relapse likelihood under multiple counterfactual scenarios.
- Regulatory validation layer aligned to FDA real-world-evidence fit-for-purpose expectations, EMA external control guidance, CONSORT-AI, STROBE-RWE, TRIPOD, and GRADE, with audit-grade traceability: confidence intervals, model explainability maps, variable importance rankings, data provenance, and uncertainty propagation metrics.
- Bias surveillance covering immortal time bias, selection bias, unmeasured confounding sensitivity, missing data mechanisms, and temporal drift, with a randomized control arm mandate when model uncertainty exceeds predefined thresholds.
- Sickle-cell disease-specific longitudinal modeling (vaso-occlusive crisis frequency, acute chest syndrome history, stroke risk, transfusion burden, ferritin trajectories, organ damage indices, hemolysis biomarkers, hydroxyurea adherence, gene therapy eligibility) against historical transfusion and transplant cohort baselines.

**Methodological innovation**

- Ethical minimization of suffering: the design restructures trials around validated historical evidence substitution for redundant control exposure while preserving scientific rigor.
- Continuous recalibration: digital twins update from incoming real-world outcomes, enabling adaptive evidence generation rather than static retrospective comparison.
- Causal balancing compiler: multi-technique ensemble (propensity, entropy, doubly robust, Bayesian) with automatic validation threshold enforcement (standardized mean difference below 0.1, calibration slope 0.9-1.1, Brier score optimization, c-index benchmarking).

**Key performance indicators**

- Synthetic control arm validity (calibration, discrimination)
- Digital twin prediction accuracy
- Placebo exposure reduction
- Trial enrollment acceleration
- Rare disease research enablement
- Sickle-cell-specific longitudinal model fidelity
- Regulatory acceptance rate

**Integration**

- Upstream: P102 (Clinical Trial Matching & Eligibility AI) for eligibility and enrollment; P91 (Genomic Variant Actionability Arbiter) for variant-informed baseline.
- Downstream: P105 (Data Sovereignty & Federated Learning Governance) for federated data governance; P109 (Health Economics & Value-Based Care Optimizer) for value-based evidence generation.

## Merits

- Establishes patient-specific digital twins and real-world evidence orchestration for regulatory-grade outcome modeling.
- Reduces placebo exposure where control assignment carries irreversible risk.
- Enables faster rare-disease trial deployment through synthetic external controls.
- Provides advanced regulatory analytics with audit-grade traceability and uncertainty quantification.
- Delivers precision population modeling, including sickle-cell longitudinal cohorts of unusual depth.

## Guidance for Use

This document records the design intent and scientific rationale of P103 (Real-World Evidence & Digital Twin Generator) as published in the CLAI-OS Tier III (Savant Precision Engine, P91–P110) compendium. The executable prompt body is withheld; nothing in this file is sufficient to operate the module. The material is released openly so that the design can be examined, critiqued, and independently validated.

Appropriate use:

- Scientific review, replication design, and methodological critique by researchers and validation groups.
- Reference for integration planning across the P-series registry.
- Citation in scholarly or institutional work describing the CLAI-OS Precision Engine.

Limitations:

- This is not a medical device, a clinical decision-support product, or a standard of care. Nothing in this document may be used to direct diagnosis, treatment, dosing, or triage for any patient.
- Genomic and oncology statements reflect only the claims made in the source compendium; publication of this documentation does not constitute independent clinical validation.
- Synthetic control methodology described here is a research design; acceptability for any regulatory submission is determined solely by the relevant agency on a fit-for-purpose basis.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
